IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Century Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.47+0.10 (+7.30%)

Close on Oct 19, 2026

Market cap: $302.49M
P/E (TTM): –
Dividend yield: –

Century Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	109	6.59	2.24	5.20	–	–
Research & Development	96	107	93	97	76	40
General & Administrative	24	33	35	32	19	9.50
Operating Expenses	126	145	149	139	95	54
Operating Income	-17	-138	-147	-134	-95	-54
Interest Expense	–	–	0.54	1.02	1.28	0.38
Interest & Investment Income	7.35	13	13	–	–	–
Other Non-Operating Income	7.62	13	12	2.99	-0.90	0.32
Asset Impairment Charges	6.76	4.33	16	–	–	–
Pretax Income	-9.65	-125	-135	-131	-96	-54
Income Tax Expense	-0.07	1.79	1.88	0.09	0.04	–
Net Income incl. Noncontrolling Interests	-9.58	-127	-137	-131	-96	-54
Net Income	-9.58	-127	-137	-131	-96	-54
EPS (Basic)(per share)	-0.14	-1.61	-2.30	-2.27	-2.96	-7.16
EPS (Diluted)(per share)	-0.14	-1.61	-2.30	-2.96	-2.96	-7.16
Shares Outstanding (Basic, Weighted)(shares)	87	79	59	58	32	7.48
Shares Outstanding (Diluted, Weighted)(shares)	87	79	59	32	32	7.48

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -107.2%
Net margin: -100.6%
Return on equity, FY2025: -6.0%

Financial strength

Current ratio: 8.28
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 329.5%

Valuation

P/E ratio: –
Price to sales: 2.77
Price to book: 1.30
Dividend yield: –